secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-09-09T11:10:06+00:00
Accession:  0001193125-26-385886
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra reports positive SURF302 data: 79% ORR, 57% CR at 60mg in FGFR3-altered NMIBC
--------------------------------------------------------------------------------

- SURF302: 60mg QD ORR 79% (11/14), CR 57% (8/14) at 3 months; 50mg ORR 67%, CR 33%.
- Safety: no Grade 4/5 TEAEs; Grade 3 treatment-related AEs in 4.5% (2/44), none at 60mg; no dose reductions at 60mg.
- Exposure-response: ORR 86% above AUC 2500 vs 58% below; supports 60mg adjuvant, 70mg cohort planned for ablative.
- Plans: complete 60mg enrollment, initiate 70mg cohort, engage health authorities; registrational adjuvant study expected 2027.
- Also: SURF303 first patient CR at 3 months; BEACH301 cleared fifth dose level in achondroplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/0001193125-26-385886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer